Valuation: BioGaia AB

Market Cap 12.18B 1.24B 1.11B 1.02B 925M 1.73B 118B 1.76B 4.89B 61.92B 4.65B 4.55B 195B P/E 2026 *
30.1x
P/E 2027 * 24.8x
Enterprise Value 11.5B 1.17B 1.05B 964M 874M 1.63B 111B 1.66B 4.62B 58.47B 4.39B 4.3B 184B EV / Sales 2026 *
6.81x
EV / Sales 2027 * 6.01x
Free-Float
80.82%
Yield 2026 *
3.41%
Yield 2027 * 3.64%
1 day+0.81%
3 months+0.73%
6 months+13.18%
Current year+13.18%
Current year 9.64
Extreme 9.64
12.45
1 year 9.64
Extreme 9.64
12.45
3 years 8.79
Extreme 8.79
12.45
5 years 7.5
Extreme 7.5
17.14
10 years 0
Extreme 0
17.14
Manager TitleAgeSince
Chief Executive Officer 60 2023-09-29
Director of Finance/CFO 59 2019-11-04
Chief Operating Officer 49 2020-12-31
Director TitleAgeSince
Chairman 77 2002-12-31
Director/Board Member 46 2014-12-31
Director/Board Member 40 2019-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.81%-.--% - - 1.24B
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +1.96%+5.90%+46.58%+84.56% 473.55B
Weighted average by Cap. +2.01%+6.60%+50.51%+100.44%

Financials

2026 *2027 *
Net sales 1.69B 172M 154M 142M 128M 240M 16.33B 244M 678M 8.59B 645M 632M 27.09B 1.91B 195M 174M 160M 145M 271M 18.47B 277M 767M 9.72B 730M 715M 30.65B
Net income 410M 41.79M 37.42M 34.42M 31.19M 58.3M 3.97B 59.39M 165M 2.09B 157M 153M 6.58B 492M 50.03M 44.81M 41.22M 37.34M 69.81M 4.75B 71.11M 197M 2.5B 188M 184M 7.88B
Net Debt -679M -69.12M -61.9M -56.94M -51.59M -96.44M -6.56B -98.24M -273M -3.45B -259M -254M -10.89B -684M -69.62M -62.36M -57.36M -51.97M -97.15M -6.61B -98.96M -275M -3.48B -261M -256M -10.97B
Projected Income Statement - Annual - BioGaia AB
Logo BioGaia AB
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.
Employees
251
Date Price Change Volume
26-10-22 US$0.000000 - 5
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - BioGaia AB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
120.40SEK
Average target price
158.00SEK
Spread / Average Target
+31.23%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BioGaia AB